University of California, Los Angeles About Us   |   Diversity and Inclusion  |   Contact Us   |   Campus Directory   |   Giving   |   Maps/Directions
Shaping the Future
RESEARCH

William Hardy, M.D.

Contact Information:

Fax Number:

310-423-4599

Work Phone Number:

310-423-3896

Mailing Address:

Cedars-Sinai Medl Cntr-Med/ID
8700 Beverly Blvd, Rm 210 Becker
Los Angeles, CA 90048
UNITED STATES

Office Address:

8700 Beverly Blvd.
1130 E
Los Angeles, CA 90048
UNITED STATES

Work Email Address:

david.hardy@cshs.org

Work Email Address:

hardyd@cshs.org

Website:

Home Page.

Director, Infectious Disease

Co-Leader, Clinical Immunology Research Laboratory (CIRL)

Associate Professor In-Residence, Infectious Diseases

Member, CTSI


A Short Biography:

David Hardy, M.D., is director of infectious diseases at Cedars-Sinai Medical Center in Los Angeles and an associate professor of medicine-in-residence at the David Geffen School of Medicine, University of California, Los Angeles (UCLA). He gained his medical degree from the Baylor College of Medicine in Houston, Texas, in 1981, completed a residency in internal medicine at Harbor-UCLA Medical Center in Torrance, California in 1984 and a clinical fellowship in infectious diseases and immunology in 1986 at UCLA School of Medicine. Later in his career he also completed a postdoctoral fellowship in basic retrovirology in 2002, also at the UCLA School of Medicine. A diplomat of the American Board of Internal Medicine, Dr. Hardy is a member of numerous professional societies including the American Academy of HIV Medicine, for whom he serves as a member of the National Board of Directors and Chairman of the California/Hawaii Chapter. He works with several community organizations, and since 1988 he has been president of the Los Angeles Physicians AIDS Forum, which he co-founded. He has served on the scientific committees for various national and international HIV congresses. Dr. Hardy has been principal investigator on a number of HIV clinical trials. Dr. Hardy has received grants or research support from Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Pfizer, and Tibotec. He has served as a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Monogram, Pfizer, and Tibotec. He has received fees for non-CME services from Gilead Sciences, Pfizer, and Tibotec. He owns stock in Merck.

Awards and Honors:

David Geffen School of Medicine, UCLA Molecular Virology
Harbor-UCLA Medical Center, Torrance, CA
Baylor College of Medicine Affiliated Hospitals, Houston, Texas
UCLA School of Medicine, Los Angeles

Selected Publications:

Miyasaki Yoko, Rabenstein John D, Rhea Joshua, Crouch Marie-Laure, Mocek Ulla M, Kittell Patricia Emmett, Morgan Margie A, Nichols Wesley Stephen, Van Benschoten M M, Hardy William David, Liu George Y Isolation and Characterization of Antimicrobial Compounds in Plant Extracts against Multidrug-Resistant Acinetobacter baumannii. PloS one. 2013; 8(4): e61594.
Wasmuth Jan-Christian, Rockstroh Jürgen Kurt, Hardy William David Drug safety evaluation of maraviroc for the treatment of HIV infection. Expert opinion on drug safety. 2012; 11(1): 161-74.
Miyasaki Yoko, Nichols W Stephen, Morgan Margie A, Kwan Jamie A, Van Benschoten M M, Kittell Patricia Emmett, Hardy W David Screening of herbal extracts against multi-drug resistant Acinetobacter baumannii. Phytotherapy research : PTR. 2010; 24(8): 1202-6.
Hardy W David, Gulick Roy M, Mayer Howard, Fätkenheuer Gerd, Nelson Mark, Heera Jayvant, Rajicic Natasa, Goodrich James Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2. Journal of acquired immune deficiency syndromes (1999). 2010; .
Holland Gary N, Vaudaux Jean D, Jeng Samuel M, Yu Fei, Goldenberg David T, Folz Ina-Caren, Cumberland William G, McCannel Colin A, Helm Craig J, Hardy W David, Hardy W David Characteristics of untreated AIDS-related cytomegalovirus retinitis. I. Findings before the era of highly active antiretroviral therapy (1988 to 1994). American journal of ophthalmology. 2008; 145(1): 5-11.
Rockstroh Jürgen Kurt, Hardy W David Antiretroviral therapy in coinfected patients: viral hepatitis and tuberculosis. Current opinion in HIV and AIDS. 2006; 1(5): 442-8.
Javaly K, Wohlfeiler M, Kalayjian R, Klein T, Bryson Y, Grafford K, Martin-Munley S, Hardy W D Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. Journal of acquired immune deficiency syndromes (1999). 1999; 21(4): 301-6.
Freedberg K A, Hardy W D, Holzman R S, Tosteson A N, Craven D E Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Medical decision making : an international journal of the Society for Medical Decision Making. 1996; 16(1): 29-35.
Hardy W D, Feinberg J, Finkelstein D M, Power M E, He W, Kaczka C, Frame P T, Holmes M, Waskin H, Fass R J A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. The New England journal of medicine. 1992; 327(26): 1842-8.
Hardy W D Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. The American journal of medicine. 1992; 92(2A): 30S-35S.
Hardy W D Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. Journal of acquired immune deficiency syndromes. 1991; 4 Suppl 1(6): S22-8.
UCLA    |    Terms & Conditions    |    Disability Resources    |    UC Regents